Sign Out
The intravenous administration of PANTOMEX i.v. is recommended only if oral application is not appropriate.
Pantoprazole is not indicated for mild gastrointestinal complaints such as nervous dyspepsia. Prior to treatment the possibility of malignancy of gastric ulcer or a malignant disease of the esophagus should be excluded as the treatment with pantoprazole may alleviate the symptoms of malignant ulcer and can thus delay diagnosis.
Diagnosis of reflux esophagitis should be confirmed by endoscopy.
The daily dose of 40 mg pantoprazole should not be exceeded in elderly patients or in those with impaired renal function. In patients with severe liver impairment the daily dose has to be reduced to 20 mg pantoprazole. Furthermore, in these patients the liver enzymes should be monitored during PANTOMEX i.v. therapy. In case of increase of the liver enzymes Pantoprazole i.v. should be discontinued.
To date there has been no experience with treatment in children.
Effect on the ability to drive and to use machines: There are no known effects on the ability to drive and use machines.
Use in Pregnancy & lactation: Clinical experience in pregnant women is limited. In animal reproduction studies, signs of slight fetotoxicity were observed at doses above 5 mg/kg. There is no information on the excretion of pantoprazole into human breast milk. Pantoprazole should only be used when the benefit to the mother is considered greater than the potential risk to the fetus/baby.
